US Bancorp DE Has $130,000 Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

US Bancorp DE decreased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 86.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,223 shares of the biopharmaceutical company’s stock after selling 39,150 shares during the period. US Bancorp DE’s holdings in Catalyst Pharmaceuticals were worth $130,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Larson Financial Group LLC raised its stake in Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 2,994 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $65,000. KBC Group NV raised its stake in Catalyst Pharmaceuticals by 48.8% in the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 1,542 shares during the period. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $134,000. Finally, Quantbot Technologies LP bought a new stake in Catalyst Pharmaceuticals in the third quarter valued at approximately $151,000. Institutional investors own 79.22% of the company’s stock.

Analysts Set New Price Targets

CPRX has been the topic of a number of recent research reports. Robert W. Baird increased their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, March 3rd. Bank of America reiterated a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $32.50.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $21.02 on Monday. The stock’s fifty day moving average price is $22.26 and its two-hundred day moving average price is $21.53. The company has a market cap of $2.55 billion, a PE ratio of 17.81, a P/E/G ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $24.64.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 44,904 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now owns 68,873 shares of the company’s stock, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.00% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.